Compare Aspen Aerogels Inc (ASPN) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aspen Aerogels Inc vs Gilead Sciences, Inc. — how do they compare? Aspen Aerogels Inc trades at $5.15 (market cap $427.65M), while Gilead Sciences, Inc. trades at $129.38 (market cap $161.19B). The key difference: Gilead Sciences, Inc. is far larger — about 376.9× Aspen Aerogels Inc's market cap, and Gilead Sciences, Inc. pays a 2.53% dividend while Aspen Aerogels Inc pays none. Which is the better fit depends on your goals.
| ASPN | GILD | |
|---|---|---|
Market Cap | $427.65M | $161.19B |
Sector | Technology | Health |
52-Week High | $8.82 | $155.80 |
52-Week Low | $2.57 | $108.22 |
Enterprise Value | $382.60M | $175.72B |
Dividend Yield | — | 2.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASPN trades at $5.16, down 1.53% on the day, with a bearish technical signal despite oversold RSI readings. The company reported a Q1 2026 loss of $0.28 per share, missing estimates, but revenue beat expectations. Recent news includes a 2025 Supplier of the Year award from General Motors and the staged restart of its East Providence facility. Financials show significant net losses but improving cash flow trends into 2026.
Outlook remains challenging with persistent losses and negative margins, though analyst consensus is strongly bullish (83% buy ratings). Key risks include execution on facility restarts and EV demand volatility. The stock offers high-risk growth potential if operational improvements and electrification trends accelerate profitability.
Gilead Sciences (GILD) trades at $129.83, down 3.72% on the day, with a bullish technical signal and strong fundamentals including a 30.99% net income margin and 43.19% ROE. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer expand its oncology portfolio, while earnings have consistently beaten estimates in recent quarters. The stock shows robust profitability and cash flow generation despite a net cash outflow in 2025.
Outlook remains positive with a consensus price target of $154.57 (19% upside), supported by analyst bullishness (67% buy ratings) and growth catalysts in HIV and oncology. Key risks include patent expirations for key drugs and competitive pressures in the biotech sector. The valuation at 17.66x P/E appears reasonable given earnings growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Aspen Aerogels Inc
Aspen Aerogels is an aerogel technology company that designs high-performance insulation. Its products are used in energy infrastructure and electric vehicles to provide thermal management and fire protection.
Read more on ASPN →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
